MGC Pharmaceuticals

MGC Pharmaceuticals is a next-generation Pharma licensed company that is revolutionizing the global plant-inspired pharmaceutical market. With headquarters in the United Kingdom, production centers in Slovenia and Malta, and research centers in Slovenia and Israel, the company stands at the forefront of research, production, and sales of innovative plant-inspired medications. MGC has successfully developed an efficient production pipeline, with three clinical arms in Neurology, Oncology, and Autoimmune. The company's goal is to provide "Cost Effective, Standardized, Affordable Medicines" and has established a full EU-GMP certified facility in Slovenia and Malta. MGC Pharmaceuticals has been making notable strides in the pharmaceutical and wellness beauty industries since its establishment in 2005. The company's commitment to quality and innovation is evident in its flagship products, including CannEpil™, CogniCann™, and Cimetra™, which are in the late stage of clinical development. With other products such as IrniCann for Glioblastoma, InCann for Crohn’s disease and colitis, and TopiCann for anti-inflammatory purposes following closely behind, MGC Pharmaceuticals continues to demonstrate a promising pipeline of pharmaceutical advancements. The company's recent £50.00KPost-IPO Debt investment at 14 July 2023 by Roby Zomer further solidifies its position in the market and signals confidence in its ongoing initiatives. MGC Pharmaceuticals' commitment to improving lives with innovative plant-inspired medicine is encapsulated in its mission and has positioned the company as a significant player in the global pharmaceutical landscape.